SynthesisPeerJ2026
Association between triglyceride-glucose index and sarcopenia: a meta-analysis.
Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With accelerating population aging, sarcopenia has become increasingly common in the elderly. Because the triglyceride-glucose index is correlated with sarcopenia, this study aims to investigate the association between the triglyceride-glucose index and sarcopenia. Methods: A systematic search of PubMed, Web of Science, Embase, and Cochrane Library databases was conducted for relevant studies published up to June 15, 2025. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model in STATA 15.0. Results: Analysis of 14 studies ( Conclusions: This meta-analysis confirms a significant association between the TyG index and sarcopenia. The prevalence of sarcopenia increases with the elevation of the TyG index. This highlights the potential value of the TyG index as a key indicator for sarcopenia screening and early intervention. Trial registration:CRD420251067364, June 25, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.